Skip to main content
. 2022 Jun;12(3):340–351. doi: 10.21037/cdt-21-724

Figure 3.

Figure 3

MI upregulates IL-1β in multiple mouse tissues, and GSK J4 suppresses this effect. IL-1β expression (pg/mL) was examined in the myocardium (A), hippocampus (B), PFC (C), and hypothalamus (D) of mice. Unlike DMSO, GSK J4 downregulated IL-1β expression in the myocardium and hippocampus. (A) In myocardial tissues, IL-1β levels were significantly higher in DMSO-treated MI mice than in DMSO-treated control mice (4,583±537.52 vs. 2,417±723.67, respectively; P=0.003), and GSK J4-treated MI mice had a much lower IL-1β expression than did DMSO-treated MI mice (2,099.55±222.84 vs. 4,583±537.52, respectively; P<0.001). (B) In hippocampal tissues, DMSO-treated MI mice had a significantly higher IL-1β expression than did DMSO-treated control mice (562.65±54.20 vs. 425.05±72.64, respectively; P=0.015), and GSK J4-treated MI mice had significantly lower IL-1β expression than did DMSO-treated mice (419.21±5.63 vs. 562.65±54.20, respectively; P=0.005). (C) In PFC tissues, DMSO-treated MI mice had a significantly higher IL-1β expression than did the control mice (1,106.09±86.22 vs. 711.20±27.57, respectively; P=0.003), and GSK J4-treated MI mice had significantly lower expression than did DMSO-treated MI mice (660.72±54.11 vs. 1,106.09±86.22 respectively; P<0.001). (D) In hypothalamus tissues, DMSO-treated MI mice had a significantly higher IL-1β expression than did the control mice (450.25±65.85 vs. 677.66±80.02 respectively; P=0.013), and GSK J4-treated mice had a significantly lower IL-1β expression compared to DMSO-treated MI mice (464.46±22.50 vs. 677.66±80.02 respectively; P=0.018). n=5 per group. Data are presented as mean ± SD. *, P<0.05. IL-1β, interleukin-1 beta; MI, myocardial infarction; DMSO, dimethylsulfoxide; PFC, prefrontal cortex; SD, standard deviation.